Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
(高级）医药代表 /（资深）产品专员 Regulär (Außendienst), Full time Innovative Medicines China Kunming (Yunnan Province) março 11, 2025 (高级 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback